RxDoctor Payments Data

Stephanie Ressler

Acute Care · Scottsdale, AZNPI 1285041509

Payments from drug & device makers

$1,561in general payments, 2019–2025

Across 36 payments — averaging $43.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$326
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$308
  • Novartis$274
  • Medtronic$236
  • ZOLL Respicardia, Inc.$179
  • Shockwave Medical, Inc$150
  • plus $88 from 4 others

What the payments were for

  • Food & beverage$1,561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,561 in reported general payments places this provider in the 70th percentile of 482 acute care providers in Arizona.

See all acute care providers in Arizona

Medicare billing

Part B allowed, 2024
$107,452
Medicare patients
584
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban332$397,308
Repatha SureclickEvolocumab97$93,686
XareltoRivaroxaban53$64,710
EntrestoSacubitril/Valsartan52$49,530
JardianceEmpagliflozin38$30,490
Praluent PenAlirocumab30$14,379
FarxigaDapagliflozin Propanediol17$13,291
Metoprolol Succinate775$10,038
VascepaIcosapent Ethyl16$9,968
Nebivolol Hcl97$7,967
Ezetimibe188$6,135
Valsartan170$6,035
Rosuvastatin Calcium320$4,286
Atorvastatin Calcium425$3,955
ClopidogrelClopidogrel Bisulfate297$3,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$397,308332 claims
NovartisEntresto$274$49,53052 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 482 acute care providers in Arizona.

Other acute care in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →